29.47USD-0.87%Mkt Cap: 1.34B USDP/E: —Last update: 2026-06-01
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combin…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.34B USD
Enterprise Value1.02B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-161.15M USD
Revenue/Share—
Last Price29.47 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees133
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.56
PEG—
EV/EBITDA-4.89
EV/Revenue—
P/S—
P/B2.82
EPS (TTM)-4.41
EPS (Forward)-4.47
52W Range
12.2482% of range33.28
52W High33.28 USD
52W Low12.24 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-35.16%
ROA-33.61%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-138.14M USD
CapEx (TTM)473.00K USD
FCF Margin—
FCF Yield-7.14%
Net Debt-304.52M USD
Net Debt/EBITDA1.45
Balance Sheet
Debt/Equity0.01
Current Ratio22.91
Quick Ratio21.71
Book Value/Sh10.41 USD
Cash/Share6.839 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)37.90 USD
Target Range28.00 USD – 48.00 USD
# Analysts10
Ownership
Shares Out.42.62M
Float13.78M
Insiders51.16%
Institutions55.99%
Short Interest
Short Ratio4.6d
Short % Float6.18%
Short % Out.3.00%
Shares Short1.36M
Short (prev mo.)1.68M
Technical
SMA 5026.18 (+12.5%)
SMA 20020.34 (+44.9%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)285.05K
Avg Vol (10d)266.09K
Technical Indicators
RSI (14)55.0
MACD0.6518
MACD Signal0.7466
MACD Hist.-0.0948
BB Upper31.42 USD
BB Middle29.02 USD
BB Lower26.63 USD
BB Width16.49%
ATR (14)2.173 USD
Vol Ratio (20d)1.19x